Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Icon ( (ICLR) ) just unveiled an update.
On September 4, 2025, ICON plc announced a leadership transition with Dr. Steve Cutler retiring as CEO, effective October 1, 2025. Barry Balfe, the current Chief Operating Officer, will succeed him and join the Board. This transition follows a comprehensive succession planning process, with Balfe’s extensive experience in the CRO industry positioning him to lead ICON into future growth. Dr. Cutler will remain on the Board as a non-executive director to ensure a smooth transition, and he expressed confidence in Balfe’s ability to drive ICON’s strategic focus on innovation and efficiency in clinical development.
The most recent analyst rating on (ICLR) stock is a Buy with a $236.00 price target. To see the full list of analyst forecasts on Icon stock, see the ICLR Stock Forecast page.
Spark’s Take on ICLR Stock
According to Spark, TipRanks’ AI Analyst, ICLR is a Outperform.
Icon’s overall stock score reflects its strong financial health and positive technical indicators, despite some challenges in revenue growth and elevated cancellations. The company’s strategic focus on growth areas and efficient operations support a favorable outlook.
To see Spark’s full report on ICLR stock, click here.
More about Icon
ICON plc is a world-leading clinical research organization headquartered in Dublin, Ireland. The company provides outsourced services to pharmaceutical, biotechnology, medical device, and government and public health organizations, focusing on advancing clinical research from molecule to medicine. As of June 30, 2025, ICON employed approximately 39,900 employees across 95 locations in 55 countries.
Average Trading Volume: 1,282,779
Technical Sentiment Signal: Sell
Current Market Cap: $13.83B
Find detailed analytics on ICLR stock on TipRanks’ Stock Analysis page.